logo-loader
RNS
Trellus Health PLC

Trellus Health PLC - Grant of Share Options

RNS Number : 3331P
Trellus Health PLC
19 January 2026
 

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Grant of Share Options

 

LONDON, U.K. AND NEW YORK, U.S. (19 January 2026). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that the Board has granted options over a total of 807,541 ordinary shares of £0.0006 in the capital of the Company (the "Share Options") to Kevin Murphy, Chairman of the Company (the "Option Holder").

 

The Share Options, which have been issued in line with the Company's existing share option plan (the "Option Plan"), have an exercise price of 0.525p per ordinary share. This is in line with the exercise price of the Loan Note, entered into with Mount Sinai on November 24, 2025. The Share Options are subject to lock-in provisions, being 12 months from the date the Share Options are exercised.

 

The Share Options vest and become exercisable in twelve (12) equal quarterly instalments (rounded up to the nearest whole share) thereafter of which the first instalment shall vest three months after the grant date and the twelfth shall vest 39 months after the vesting commencement date.

 

The Share Options are subject to the rules of the Option Plan and the relevant award documentation, including customary good leaver and bad leaver provisions.

 

The independent directors consider that the award is fair and reasonable insofar as the Company's shareholders are concerned and believe it appropriately aligns the Chairman's interests with those of shareholders.

 

Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement released on 30 December 2025.

 

For further information please contact:

 

Trellus Health plc

https://trellushealth.com/

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder

Via Walbrook PR

Joy Bessenger, Chief Financial Officer




Singer Capital Markets (Nominated Adviser and Broker)

Tel: +44 (0)20 7496 3000

Philip Davies / James Todd / Patrick Weaver




Walbrook PR

Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com

Paul McManus / Lianne Applegarth /

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/

+44 (0)7407 804 654

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Kevin Laurence Murphy

2

 

Reason for the notification

 

a)

 

Position/status

 

Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Trellus Health plc

b)

 

LEI

 

2138002FHWJSR8YKP295

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Options over ordinary shares of £0.0006 each in the Company



Identification code

GB00BNNFM402


b)

 

Nature of the transaction

 

 

Grant of options over shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




£0.00525 exercise price

807,541







d)

 

Aggregated information

 

 

 

 



- Aggregated volume

N/A



- Price

N/A



e)

 

Date of the transaction

 

 

16 January 2026

f)

 

Place of the transaction

 

 

Outside of trading venue - off market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBPMBTMTBBTJF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read